LifeMD Q3 revenue misses analyst estimates, lowers FY outlook
LFMD•LifeMD reported Q3 revenue of $44.6 million, down 7% year over year and below the $48.89 million analyst estimate. It lowered its 2026 revenue outlook to $188 million-$191 million from $205.5 million-$212.5 million.
1. Q3 results
LifeMD's Q3 revenue fell 7% year over year to $44.6 million, missing the $48.89 million analyst estimate. Adjusted EBITDA was a loss of $413,000, and gross margin was 82%.
2. Outlook and drivers
The company expects Q4 revenue of $46 million to $49 million and an adjusted EBITDA loss of $4 million to $2 million. It lowered its 2026 revenue outlook to $188 million-$191 million from $205.5 million-$212.5 million, citing reduced marketing spending and a slower-than-expected ramp-up of new partnerships. LifeMD said pharmacy shipment volume grew 58.3% year over year, supporting subscriber growth.
